drugset / Trial / NCT07611214
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
Timeline
- Start
- 2026-04-22
- Primary completion
- 2029-03-02
- Completion
- 2029-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anifrolumab | Monoclonal antibody | — | — |
| Subject | Belimumab | Monoclonal antibody | — | — |
| Subject | Obinutuzumab | Monoclonal antibody | — | — |
| Subject | Voclosporin | Other / unclassified | — | — |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | mycophenolic acid | Small molecule | — | — |